A detailed history of Hsbc Holdings PLC transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 14,341 shares of BEAM stock, worth $359,242. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,341
Holding current value
$359,242
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$21.22 - $32.66 $304,316 - $468,377
14,341 New
14,341 $336,000
Q3 2023

Nov 13, 2023

SELL
$23.01 - $32.46 $378,767 - $534,324
-16,461 Reduced 48.81%
17,261 $415,000
Q2 2023

Aug 11, 2023

BUY
$29.32 - $35.99 $509,698 - $625,650
17,384 Added 106.4%
33,722 $1.08 Million
Q1 2023

May 15, 2023

BUY
$30.15 - $48.79 $492,590 - $797,131
16,338 New
16,338 $500,000
Q2 2022

Aug 11, 2022

BUY
$29.86 - $62.36 $169,336 - $353,643
5,671 New
5,671 $221,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.76B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Hsbc Holdings PLC Portfolio

Follow Hsbc Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.